APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Pharmaceuticals : Excerpt from corporate presentation dated January 2022 - Form 8-K

01/10/2022 | 08:08am EDT

EMPAVELI commercial launch off to a strong start As of December 31, 2021: >95% patient compliance rate >125 start forms submitted FY 2021 U.S. Net Product Sales >75% of C5 switches from Ultomiris ~$15 Million1 • C5 inhibitor switch patients are majority of new EMPAVELI starts Zero cases of meningococcal infection 1. Estimated 2021 EMPAVELI U.S. net product sales are unaudited, preliminary and based on management's estimate as of the date of this presentation and are subject to completion of the Company's financial closing procedures. 16

Disclaimer

Apellis Pharmaceuticals Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 13:07:04 UTC.


© Publicnow 2022
All news about APELLIS PHARMACEUTICALS, INC.
05/12Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Ass..
GL
05/12Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Ass..
AQ
05/11TRANSCRIPT : Apellis Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Con..
CI
05/09Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
05/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
05/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
AQ
05/05Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Co..
GL
05/05Raymond James Adjusts Apellis Pharmaceuticals' Price Target to $102 from $114, Keeps St..
MT
05/05Credit Suisse Raises Apellis Pharmaceuticals' PT to $44 from $40, Says On Track to Subm..
MT
05/05Wedbush Lifts Apellis Pharmaceuticals' Price Target to $40 From $39, Maintains Neutral ..
MT
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 92,9 M - -
Net income 2022 -580 M - -
Net cash 2022 426 M - -
P/E ratio 2022 -7,78x
Yield 2022 -
Capitalization 4 636 M 4 636 M -
EV / Sales 2022 45,3x
EV / Sales 2023 15,6x
Nbr of Employees 476
Free-Float 83,0%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | APLS | US03753U1060 | MarketScreener
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 43,52 $
Average target price 72,07 $
Spread / Average Target 65,6%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.-7.95%4 636
CSL LIMITED-6.06%91 946
SAMSUNG BIOLOGICS CO.,LTD.-11.85%44 385
BIOGEN INC.-18.43%28 662
WUXI BIOLOGICS (CAYMAN) INC.-42.79%28 457
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-26.31%22 129